Table 2 Comparisons between groups at the end of the study
From: Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial
BDP/F 400/24 μg/day (N = 206) | FP/S 500/100 μg/day (N = 216) | Between group p value | |
|---|---|---|---|
FEV1, L | 2.92 (0.04) | 2.92 (0.03) | 0.938 |
FEV1% predicted | 85.90 (0.98) | 85.70 (0.98) | 0.878 |
PEF, L/min | 442.47 (4.57) | 440.21 (4.55) | 0.699 |
PEF % predicted | 96.87 (1.46) | 98.43 (1.32) | 0.428 |
Daytime symptoms scorea | 1.37 (0.07) | 1.32 (0.06) | 0.609 |
Night-time symptom scorea | 1.33 (0.11) | 1.46 (0.10) | 0.368 |
symptom-free days, % | 93.66 (1.13) | 92.47 (1.11) | 0.451 |
Controlled asthmab, n (%) | 163 (90.0) | 167 (85.2) | 0.362 |
Partly controlled asthmab, % | 11 (6.0) | 18 (9.2) | |
Uncontrolled asthmab, % | 7 (4.0) | 11 (5.6) |